Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals

Blood

Volumn 109, Issue 10, 2007, Pages 4296-4305

  Ravet, Sophie ^a,b   Scott Algara, Daniel ^c   Bonnet, Elodie ^a   Hung, Khiem Tran ^d   Tran, Ton ^d,f   Nguyen, Ngai ^e   Lien, Xuan Truong ^d   Theodorou, Ioannis ^f   Barré Sinoussi, Françoise ^c   Pancino, Gianfranco ^c   Paul, Pascale ^a,b,g  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR   (France)

^d PASTEUR INSTITUTE   (Viet Nam)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f Binh Trieu Hospital   (Viet Nam)

^g HÔPITAL DE LA CONCEPTION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; NATURAL KILLER CELL RECEPTOR;

ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; CELL COMPARTMENTALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEGRANULATION; DOWN REGULATION; DRUG USE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIET NAM;

EID: 34248368553     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-08-040238     Document Type: Article

References (43)

1. Bottino C, Moretta L, Moretta A. NK cell activating receptors and tumor recognition in humans. Curr Top Microbiol Immunol. 2006;298:175-182.
2. Stewart CA, Vivier E, Colonna M. Strategies of natural killer cell recognition and signaling. Curr Top Microbiol Immunol. 2006;298:1-21.
3. Lodoen MB, Lanier LL. Natural killer cells as an initial defense against pathogens. Curr Opin Immunol. 2006;18:391-398.
4. Lanier LL. Natural killer cells: roundup. Immunol Rev. 2006;214:5-8.
5. Parham P. Taking license with natural killer cell maturation and repertoire development. Immunol Rev. 2006;214:155-160.
6. Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med. 2006;203:633-645.
7. Thananchai H, Gillespie G, Martin MP, et al. Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol. 2007;178:33-37.
8. Khakoo SI, Carrington M. KIR and disease: a model system or system of models? Immunol Rev. 2006;214:186-201.
9. Anfossi N, Andre P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006;25:331-342.
10. Stewart CA, Laugier-Anfossi F, Vely F, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A. 2005;102:13224-13229.
11. Fogli M, Costa P, Murdaca G, et al. Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1-infected patients. Eur J Immunol. 2004;34:2313-2321.
12. De Maria A, Fogli M, Costa P, et al. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol. 2003;33:2410-2418.
13. Mavilio D, Benjamin J, Daucher M, et al. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A. 2003;100:15011- 15016.
14. Weber K, Meyer D, Grosse V, Stoll M, Schmidt RE, Heiken H. Reconstitution of NK cell activity in HIV-1 infected individuals receiving antiretroviral therapy. Immunobiology. 2000;202:172-178.
15. Sondergaard SR, Aladdin H, Ullum H, Gerstoft J, Skinhoj P, Pedersen BK. Immune function and phenotype before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 1999;21:376-383.
16. Sirianni MC, Ensoli F, Alario C, et al. Distribution of the natural killer-related receptor for HLA-C during highly active antiretroviral therapy for human immunodeficiency virus infection. Hum Immunol. 2001;62:1328-1334.
17. Mendila M, Heiken H, Becker S, et al. Immunologic and virologic studies in long-term nonprogressors with HIV-1 infection. Eur J Med Res. 1999;4:417-424.
18. Martin MP, Gao X, Lee JH, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet. 2002;31:429-434.
19. Scott-Algara D, Truong LX, Versmisse P, et al. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol. 2003;171:5663-5667.
20. Jennes W, Verheyden S, Demanet C, et al. Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J Immunol. 2006;177:6588-6592.
21. Truong LX, Luong TT, Scott-Algara D, et al. CD4 cell and CD8 cell-mediated resistance to HIV-1 infection in exposed uninfected intravascular drug users in Vietnam. AIDS. 2003;17:1425-1434.
22. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294:15-22.
23. Uhrberg M. The CD107 mobilization assay: viable isolation and immunotherapeutic potential of tumor-cytolytic NK cells. Leukemia. 2005;19:707-709.
24. Pascal V, Schleinitz N, Brunet C, et al. Comparative analysis of NK cell subset distribution in normal and lymphoproliferative disease of granular lymphocyte conditions. Eur J Immunol. 2004;34:2930-2940.
25. Toneva M, Lepage V, Lafay G, et al. Genomic diversity of natural killer cell receptor genes in three populations. Tissue Antigens. 2001;57:358-362.
26. Hsu KC, Liu XR, Selvakumar A, Mickelson E, O'Reilly RJ, Dupont B. Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol. 2002;169:5118-5129.
27. + cells in sexually HIV-1-exposed but uninfected individuals. Clin Immunol. 2006.
28. Alter G, Malenfant JM, Delabre RM, et al. Increased natural killer cell activity in viremic HIV-1 infection. J Immunol. 2004;173:5305-5311.
29. Jacobs R, Weber K, Wendt K, Heiken H, Schmidt RE. Altered coexpression of lectin-like receptors CD94 and CD161 on NK and T cells in HIV patients. J Clin Immunol. 2004;24:281-286.
30. Ljutic B, Carlyle JR, Filipp D, Nakagawa R, Julius M, Zuniga-Pflucker JC. Functional requirements for signaling through the stimulatory and inhibitory mouse NKR-P1 (CD161) NK cell receptors. J Immunol. 2005;174:4789-4796.
31. Rosen DB, Bettadapura J, Alsharifi M, Mathew PA, Warren HS, Lanier LL. Cutting edge: lectinlike transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. J Immunol. 2005;175:7796-7799.
32. Aldemir H, Prod'homme V, Dumaurier MJ, et al. Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor. J Immunol. 2005;175:7791-7795.
33. Azzoni L, Zatsepina O, Abebe B, Bennett IM, Kanakaraj P, Perussia B. Differential transcriptional regulation of CD161 and a novel gene, 197/15a, by IL-2, IL-15, and IL-12 in NK and T cells. J Immunol. 1998;161:3493-3500.
34. Bonaparte MI, Barker E. Killing of human immunodeficiency virus-infected primary T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the expression of major histocompatibility complex class I molecules. Blood. 2004;104:2087-2094.
35. Mela CM, Burton CT, Imami N, et al. Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapy. AIDS. 2005;19:1761-1769.
36. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004;305:872-874.
37. Carr WH, Rosen DB, Arase H, Nixon DF, Michaelsson J, Lanier LL. Cutting edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. J Immunol. 2007;178:647-651.
38. Gaudieri S, DeSantis D, McKinnon E, et al. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun. 2005;6:683-690.
39. O'Connor G M, Guinan KJ, Cunningham RT, Middleton D, Parham P, Gardiner CM. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J Immunol. 2007;178:235-241.
40. Andre P, Brunet C, Guia S, et al. Differential regulation of killer cell Ig-like receptors and CD94 lectin-like dimers on NK and T lymphocytes from HIV-1-infected individuals. Eur J Immunol. 1999;29:1076-1085.
41. Fauci AS, Mavilio D, Kottilil S. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat Rev Immunol. 2005;5:835-843.
42. Tran HK, Chartier L, Troung LX, et al. Systemic immune activation in HIV-1-exposed uninfected Vietnamese intravascular drug users. AIDS Res Hum Retroviruses. 2006;22:255-261.
43. Follezou JY, Lan NY, Lien TX, et al. Clinical and biological characteristics of human immunodeficiency virus-infected and uninfected intravascular drug users in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg. 1999;61:420-424.